# RAP2A

## Overview
RAP2A is a gene that encodes a protein belonging to the Ras family of small GTPases, which are pivotal in regulating various cellular processes such as cell adhesion, proliferation, and immune response. The RAP2A protein is involved in the modulation of the actin cytoskeleton and cell adhesion, influencing cell migration and growth. It is primarily active in the cytoplasm and at the plasma membrane, where it participates in intracellular signaling pathways that affect cell polarity and exocytosis (Gloerich2011Regulating). In addition to its role in normal cellular functions, RAP2A is implicated in oncogenic pathways, contributing to cancer cell migration, invasion, and drug resistance. It interacts with several proteins, including MAP4K4, MINK, and TNIK, which are crucial for maintaining synaptic structure and function (Hussain2010MINK). The gene's expression and interactions are significant in various cancers, where it can act as an oncogene or potentially as a tumor suppressor, depending on the context (Wu2015Rap2a; Kumari2021Molecular).

## Function
RAP2A, a member of the Ras family of small GTPases, plays a significant role in various cellular processes, including cell adhesion, proliferation, and immune response regulation. In healthy human cells, RAP2A is involved in the regulation of the actin cytoskeleton and cell adhesion, influencing cell migration and growth (Gloerich2011Regulating). It is active in the cytoplasm and at the plasma membrane, where it participates in intracellular signaling pathways that affect cell polarity and exocytosis (Gloerich2011Regulating).

RAP2A is also implicated in the modulation of immune responses. In macrophages, it regulates NF-κB activity, a critical transcription factor in inflammatory responses. Both knock-down and overexpression of RAP2A impair NF-κB activity, suggesting a complex regulatory role in maintaining balanced immune responses (Carvalho2019Both). RAP2A is activated by lipopolysaccharide (LPS) in macrophages, influencing the production of inflammatory cytokines and chemokines, which are essential for the innate immune response (Carvalho2019Both).

In endothelial cells, RAP2A affects barrier resistance by modulating junctional permeability, acting antagonistically to Rap1, which enhances barrier resistance (Pannekoek2013Rap1). This balance between RAP2A and Rap1 is crucial for controlling endothelial barrier function.

## Clinical Significance
RAP2A, a member of the RAS oncogene family, plays a significant role in various cancers due to its altered expression and interactions. In hepatocellular carcinoma (HCC), RAP2A is upregulated and acts as an oncogene, promoting cell proliferation and resistance to apoptosis through the mTOR signaling pathway. Its expression correlates with poor prognosis, advanced tumor grade, and increased metastasis (Yang2021RAP2A; Kumari2021Molecular). RAP2A is also associated with higher levels of alpha-fetoprotein (AFP) and genetic alterations such as TP53 mutations, which further enhance its expression (Kumari2021Molecular).

In renal cell carcinoma (RCC), RAP2A overexpression enhances cell migration and invasion, potentially through the Akt signaling pathway, and is linked to increased metastasis (Wu2017Rap2a). In gastric cancer, RAP2A contributes to cisplatin resistance by promoting cell survival and invasive properties, suggesting its role in drug resistance (Zhang2019Knockdown).

RAP2A's involvement in cancer is complex, as it can act as an oncogene in several cancers, including prostate, lung, bladder, gastric, and renal cancers, while potentially serving as a tumor suppressor in glioma (Kumari2021Molecular). Its expression is regulated by p53 and is associated with the activation of matrix metalloproteinases MMP2 and MMP9, which are crucial for tumor cell invasion and metastasis (Wu2015Rap2a).

## Interactions
RAP2A, a member of the RAS oncogene family, is involved in various protein interactions that influence cellular processes. It interacts with MAP4K4, MINK, and TNIK, which are involved in the regulation of neuronal structure and function. These interactions are crucial for maintaining synaptic structure and AMPA receptor function, with MINK and TNIK acting as scaffolds in the postsynaptic density (Hussain2010MINK). RAP2A also interacts with PLCe, which is implicated in lung cancer development, highlighting its role in oncogenic pathways (Nakhaei-Rad2018Structural).

In cancer cell migration and invasion, RAP2A is a target of miR-33a-5p, a microRNA that acts as a tumor suppressor in pancreatic ductal adenocarcinoma. The interaction between miR-33a-5p and RAP2A is confirmed through luciferase reporter assays and RNA immunoprecipitation, indicating that miR-33a-5p suppresses RAP2A expression, thereby inhibiting cancer cell proliferation and invasion (Lian2021Tumor).

RAP2A is also involved in the PI3K/Akt signaling pathway, where its overexpression increases Akt phosphorylation, enhancing cancer cell motility and invasion. This interaction is crucial for the secretion of matrix metalloproteinases MMP2 and MMP9, which are essential for tumor cell invasion (Wu2015Rap2a).


## References


[1. (Wu2015Rap2a) Jin-Xia Wu, Ding-Guo Zhang, Jun-Nian Zheng, and Dong-Sheng Pei. Rap2a is a novel target gene of p53 and regulates cancer cell migration and invasion. Cellular Signalling, 27(6):1198–1207, June 2015. URL: http://dx.doi.org/10.1016/j.cellsig.2015.02.026, doi:10.1016/j.cellsig.2015.02.026. This article has 28 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.cellsig.2015.02.026)

[2. (Hussain2010MINK) Natasha K. Hussain, Honor Hsin, Richard L. Huganir, and Morgan Sheng. Mink and tnik differentially act on rap2-mediated signal transduction to regulate neuronal structure and ampa receptor function. The Journal of Neuroscience, 30(44):14786–14794, November 2010. URL: http://dx.doi.org/10.1523/JNEUROSCI.4124-10.2010, doi:10.1523/jneurosci.4124-10.2010. This article has 76 citations.](https://doi.org/10.1523/JNEUROSCI.4124-10.2010)

[3. (Kumari2021Molecular) Sarita Kumari, Mohit Arora, Jay Singh, Lokesh K. Kadian, Rajni Yadav, Shyam S. Chauhan, and Anita Chopra. Molecular associations and clinical significance of raps in hepatocellular carcinoma. Frontiers in Molecular Biosciences, June 2021. URL: http://dx.doi.org/10.3389/fmolb.2021.677979, doi:10.3389/fmolb.2021.677979. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmolb.2021.677979)

[4. (Gloerich2011Regulating) Martijn Gloerich and Johannes L. Bos. Regulating rap small g-proteins in time and space. Trends in Cell Biology, 21(10):615–623, October 2011. URL: http://dx.doi.org/10.1016/j.tcb.2011.07.001, doi:10.1016/j.tcb.2011.07.001. This article has 132 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.tcb.2011.07.001)

[5. (Pannekoek2013Rap1) Willem-Jan Pannekoek, Jelena R. Linnemann, Patricia M. Brouwer, Johannes L. Bos, and Holger Rehmann. Rap1 and rap2 antagonistically control endothelial barrier resistance. PLoS ONE, 8(2):e57903, February 2013. URL: http://dx.doi.org/10.1371/journal.pone.0057903, doi:10.1371/journal.pone.0057903. This article has 44 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0057903)

[6. (Yang2021RAP2A) Jing-ru Yang, Xiao-ling Ling, and Quan-lin Guan. Rap2a promotes apoptosis resistance of hepatocellular carcinoma cells via the mtor pathway. Clinical and Experimental Medicine, 21(4):545–554, May 2021. URL: http://dx.doi.org/10.1007/s10238-021-00723-x, doi:10.1007/s10238-021-00723-x. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10238-021-00723-x)

[7. (Wu2017Rap2a) Jin-Xia Wu, Wen-Qi Du, Xiu-Cun Wang, Lu-Lu Wei, Fu-Chun Huo, Yao-Jie Pan, Xiao-Jin Wu, and Dong-Sheng Pei. Rap2a serves as a potential prognostic indicator of renal cell carcinoma and promotes its migration and invasion through up-regulating p-akt. Scientific Reports, July 2017. URL: http://dx.doi.org/10.1038/s41598-017-06162-7, doi:10.1038/s41598-017-06162-7. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-017-06162-7)

[8. (Carvalho2019Both) Brener C. Carvalho, Leonardo C. Oliveira, Carolina D. Rocha, Heliana B. Fernandes, Isadora M. Oliveira, Felipe B. Leão, Thalita M. Valverde, Igor M.G. Rego, Sankar Ghosh, and Aristóbolo M. Silva. Both knock-down and overexpression of rap2a small gtpase in macrophages result in impairment of nf-κb activity and inflammatory gene expression. Molecular Immunology, 109:27–37, May 2019. URL: http://dx.doi.org/10.1016/j.molimm.2019.02.015, doi:10.1016/j.molimm.2019.02.015. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.molimm.2019.02.015)

[9. (Zhang2019Knockdown) Jinyu Zhang, Yunhai Wei, Jie Min, Yan Wang, Lei Yin, Guoliang Cao, and Hua Shen. Knockdown of rap2a gene expression suppresses cisplatin resistance in gastric cancer cells. Oncology Letters, November 2019. URL: http://dx.doi.org/10.3892/ol.2019.11086, doi:10.3892/ol.2019.11086. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ol.2019.11086)

[10. (Nakhaei-Rad2018Structural) Saeideh Nakhaei-Rad, Fereshteh Haghighi, Parivash Nouri, Soheila Rezaei Adariani, Jana Lissy, Neda S. Kazemein Jasemi, Radovan Dvorsky, and Mohammad Reza Ahmadian. Structural fingerprints, interactions, and signaling networks of ras family proteins beyond ras isoforms. Critical Reviews in Biochemistry and Molecular Biology, 53(2):130–156, February 2018. URL: http://dx.doi.org/10.1080/10409238.2018.1431605, doi:10.1080/10409238.2018.1431605. This article has 38 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/10409238.2018.1431605)

[11. (Lian2021Tumor) Yanfen Lian, Dongxiao Jiang, and Jiangtao Sun. Tumor suppressive role of mir-33a-5p in pancreatic ductal adenocarcinoma cells by directly targeting rap2a. Cellular &amp; Molecular Biology Letters, June 2021. URL: http://dx.doi.org/10.1186/s11658-021-00265-w, doi:10.1186/s11658-021-00265-w. This article has 9 citations.](https://doi.org/10.1186/s11658-021-00265-w)